Oruka Therapeutics, Inc. (ORKA)

Market Cap	746.14M
Revenue (ttm)	n/a
Net Income (ttm)	n/a
Shares Out	29.40M
EPS (ttm)	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	23,327
Open	25.60
Previous Close	26.47
Day's Range	25.20 - 26.41
52-Week Range	18.72 - 53.88
Beta	n/a
Analysts	Strong Buy
Price Target	41.33 (+62.85%)
Earnings Date	n/a

About ORKA

Oruka Therapeutics, Inc., a biotechnology company, develops novel biologics for the treatment of chronic skin diseases. Its lead products include ORKA-001 that targets p19 subunit of interleukin-23 (IL-23p19); and ORKA-002 that targets interleukin-17A and interleukin-17F (IL-17A/F) for the treatment of psoriasis psoriatic arthritis, and other inflammatory diseases. The company is based in Waltham, Massachusetts.

• Founded: 2004
• Country: United States
• Stock Exchange: NASDAQ
• Ticker Symbol: ORKA
• Website: https://orukatx.com

Financial Performance

Financial numbers in USD

Analyst Forecast

According to 4 analysts, the average rating for ORKA stock is "Strong Buy." The 12-month stock price forecast is $41.33, which is an increase of 62.85% from the latest price.

Price Target

$41.33

(62.85% upside)

Analyst Consensus: Strong Buy